Clario explores how Neuroimaging and Precision Motion wearable sensor tech can characterize digital endpoints for PD trials MDS 2022

Exploration of neuromelanin MRI and Opal® sensor technology can improve the quality and precision of clinical outcome measures

PHILADELPHIA, PA – September 15, 2022 – Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced it will present findings from three research studies at the 2022 International Congress of Parkinson’s Disease and Movement Disorders (MDS). Scientists from Clario’s Precision Motion and Imaging Science Teams will share their research during the following poster presentation sessions. 

• Gait Characteristics from Daily Life Increase Ability to Predict Future Falls in People with Parkinson’s Disease (Poster #770, Station 21) – September 16 
  • Session discusses findings on the importance of precise digital measures captured via sensors on the feet and lower back to quantify aspects of gait during daily life to improve classification of future fallers with PD

• Digital Sway Measures for Spinocerebellar Ataxia (Poster #458, Station GPT 7) – September 16 
  • Discussion on research that determined sway measures from sternum sensors during the standing, feet-together condition are most sensitive to prodromal and manifest spinocerebellar ataxia (SCA) and that the best sway measures reflecting balance control of SCA were ellipse area and average velocity

• Characterization of Neuromelanin MRI as a Potential Parkinson’s Disease Biomarker in a Multi-Site Longitudinal Study (Virtual poster) – September 15 
  • Session discusses findings that show longitudinal effects are small and variable with inter-vendor differences in neuromelanin MRI in substantia nigra pars compacta (SNpc) in PD patients

Registered attendees can view the posters on the event’s virtual platform.

Researchers from the above studies will continue their discussion on Neuroimaging and measuring mobility in patients with Parkinson’s Disease during a free live webinar on Friday, September 23rd at 11 a.m. EST. The session will explore the practical applications of precision motion approaches and sensor-enabled instrumented tests to measure performance outcome clinical outcome assessments for Parkinson’s disease. Attendees will understand how performance outcome assessments of functional mobility can provide insights on the patient-reported Quality of Life impact and clinically meaningful outcome measures in Parkinson’s disease trials.

The session will be led by:

• Kristen Sowalsky, Ph.D., D.C., Director Clinical Science and Consulting, Clario 
• Fay Horak, Ph.D., P.T., Chief Scientist, Consulting, Clario 
• Martina Mancini, Ph.D., Expert Consultant, PD, Consulting, Clario 
• Madhura Ingalhalikar Ph.D., MRI Scientist, Neuroscience Medical Affairs, Clario 
• Diane Stephenson, Ph.D., Critical Path Institute 

The webinar will include a live Q&A session with the panelists. Register here to reserve your seat for Advances in Precision Motion and Imaging Clinical Trial Endpoints Collection for Parkinson’s Disease.